These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 29157620)

  • 1. Unicentric Castleman Disease.
    Wong RSM
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):65-73. PubMed ID: 29157620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study.
    Sopfe J; Endres A; Campbell K; Hayes K; Trout AT; Liang X; Lorsbach R; O'Brien MM; Cost CR
    Pediatr Blood Cancer; 2019 May; 66(5):e27613. PubMed ID: 30680887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaline vascular variant of unicentric Castleman disease of the tonsil: a case report.
    Li P; Liu H; Li H; Li A; Yu G; Yin W
    Diagn Pathol; 2019 Jun; 14(1):70. PubMed ID: 31253137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases.
    Boutboul D; Fadlallah J; Chawki S; Fieschi C; Malphettes M; Dossier A; Gérard L; Mordant P; Meignin V; Oksenhendler E; Galicier L
    Br J Haematol; 2019 Jul; 186(2):269-273. PubMed ID: 31016730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of Castleman disease.
    Soumerai JD; Sohani AR; Abramson JS
    Cancer Control; 2014 Oct; 21(4):266-78. PubMed ID: 25310208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features and treatment outcomes of Castleman disease in children: a retrospective cohort in China.
    Hu S; Li Z; Wang H; Chen L; Ma Y; Zhu X; Li J; Dong R; Yao W; Dong C; Zhang H; Li K; Dong K; Zhai X
    Eur J Pediatr; 2023 Dec; 182(12):5519-5530. PubMed ID: 37782352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature.
    Bowne WB; Lewis JJ; Filippa DA; Niesvizky R; Brooks AD; Burt ME; Brennan MF
    Cancer; 1999 Feb; 85(3):706-17. PubMed ID: 10091744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unicentric Castleman disease presenting as a retroperitoneal peripancreatic mass: A report of two cases and review of literature.
    Cheng JL; Cui J; Wang Y; Xu ZZ; Liu F; Liang SB; Tian H
    World J Gastroenterol; 2018 Sep; 24(34):3958-3964. PubMed ID: 30228787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
    Abid MB; Peck R; Abid MA; Al-Sakkaf W; Zhang Y; Dunnill GS; Staines K; Sequeiros IM; Lowry L
    Hematol Oncol; 2018 Feb; 36(1):320-323. PubMed ID: 28401573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unicentric Castleman disease: A case report of an atypical presentation and successful management.
    Muhammad T; Alkheder A; Mazloum A; Almooay A; Naziha L; Shaheen M
    Int J Surg Case Rep; 2024 May; 118():109688. PubMed ID: 38669805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathology of Castleman Disease.
    Wu D; Lim MS; Jaffe ES
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):37-52. PubMed ID: 29157618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Castleman Disease: A Multicenter Case Series from Turkey.
    Gündüz E; Kırkızlar HO; Ümit EG; Karaman Gülsaran S; Özkocaman V; Özkalemkaş F; Candar Ö; Elverdi T; Küçükyurt S; Paydaş S; Çeneli Ö; Karakuş S; Maral S; Ekinci Ö; İpek Y; Kis C; Güven ZT; Akdeniz A; Celkan T; Eroğlu Küçükdiler AH; Akgün Çağlıyan G; Özçelik Şengöz C; Karataş A; Bulduk T; Özcan A; Belen Apak FB; Canbolat A; Kartal İ; Ören H; Töret E; Özdemir GN; Bakanay Öztürk ŞM
    Turk J Haematol; 2022 Jun; 39(2):130-135. PubMed ID: 35176839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Rare Lymphoproliferative Disease: Castleman Disease.
    Gündüz E; Özdemir N; Bakanay ŞM; Karakuş S
    Turk J Haematol; 2021 Dec; 38(4):314-320. PubMed ID: 34719151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
    Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
    Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence in unicentric castleman's disease postoperatively: a case report and literature review.
    Ren N; Ding L; Jia E; Xue J
    BMC Surg; 2018 Jan; 18(1):1. PubMed ID: 29301533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Management of Castleman Disease.
    Abramson JS
    J Natl Compr Canc Netw; 2019 Nov; 17(11.5):1417-1419. PubMed ID: 31766018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The full spectrum of Castleman disease: 273 patients studied over 20 years.
    Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
    Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy.
    Chronowski GM; Ha CS; Wilder RB; Cabanillas F; Manning J; Cox JD
    Cancer; 2001 Aug; 92(3):670-6. PubMed ID: 11505414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital.
    González-García A; Patier de la Peña JL; García-Cosio M; Sarhane Y; Sánchez Díaz C; Barbolla Díaz I; López Rodríguez M; Moreno MÁ; Villarubia J; Manzano L
    Leuk Lymphoma; 2019 Dec; 60(14):3442-3448. PubMed ID: 31305183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Castleman Disease.
    Wang W; Medeiros LJ
    Surg Pathol Clin; 2019 Sep; 12(3):849-863. PubMed ID: 31352991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.